Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of M-001 influenza vaccine in adults aged 50 years and older
2018-000468-27Phase 3Completed
- Sponsor
- Scinai Immunotherapeutics Ltd.
- Start
- Mar 2018
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing M-001 with Placebo (2 arms). Primary endpoints: Solicited local and systemic reactogenicity events and Serious adverse events, medically attended adverse events, and new-onset chronic illnesses. Started Mar 2018; status: completed.
02
Drugs
multimeric-001
03
Conditions
influenza
Beyond the preview
Go deeper on 2018-000468-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000468-27.